3 terminated, 2 completed, 1 active not recruiting, 1 unknown. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Terminated 3, Completed 2, Active not recruiting 1, Unknown 1 |
Follow lorcaserin: new trials by email Literature Review of lorcaserin trials Research Report on lorcaserin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Predictors of Lorcaserin-Induced Weight Loss Belviq, Placebo - Overweight and Obesity | Phase 4 | Terminated | Columbia University | 32 | 2018-01-03 | 2024-03-27 |
| Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years lorcaserin hydrochloride XR, Placebo - Obesity | Phase 4 | Terminated | Eisai Inc. | 278 | 2017-09-28 | 2021-07-19 |
| MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Lorcaserin, Metformin, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 4 | Terminated | University of North Carolina, Chapel Hill | 71 | 2016-09-01 | 2021-03-03 |
| Lorcaserin in Obesity: Identification of CNS Targets Using fMRI Lorcaserin HCl, Placebo - Obesity, Weight Loss | Phase 4 | Active not recruiting | Beth Israel Deaconess Medical Center | 40 | 2014-10-01 | 2026-05-01 |
| A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Lorcaserin hydrochloride, Placebo - Cardiovascular Disease, High Cardiovascular Risk | Phase 4 | Completed | Eisai Inc. | 14673 | 2014-01-24 | 2019-07-16 |
| Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study lorcaserin, Intensive dietary counseling - Weight Gain | Phase 4 | Unknown | Southern California Institute for Research and Education | 15 | 2014-01-01 | 2014-01-30 |
| A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl - Chronic Weight Management | Phase 4 | Completed | Eisai Inc. | 344 | 2013-10-30 | 2019-09-30 |
Obesity (6) · Overweight (4) · Weight Loss (4) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Psychotic Disorders (1) · Schizophrenia (1) · Weight Gain (1)
Eisai Inc. (3) · Beth Israel Deaconess Medical Center (1) · Columbia University (1) · Southern California Institute for Research and Education (1) · University of North Carolina, Chapel Hill (1)
United States (7) · Australia (1) · Canada (1) · Chile (1) · Mexico (1) · New Zealand (1) · Poland (1) · The Bahamas (1)
Christos S Mantzoros, MD DSc (1) · Lars F. Jarskog, MD (1) · Sharon Wardlaw, MD (1)
PMID 27385157, PMID 28440045, PMID 29363287, PMID 29803985, PMID 30145941, PMID 30293771, PMID 30586726, PMID 36897161
R01DK093920 (1), R01DK105526 (1)